Blood Advances

Article	Citations
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.	248
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6)	146
Addressing and overcoming disparities in GVHD	137
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection	133
On a collision course: SARS-CoV-2 variants and CAR T cells	127
Cortisol in sickle cell disease: a systematic review and meta-analysis	121
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenström macroglobulinemia: a pooled analysis	120
Desensitization to calaspargase pegol appears to be less successful than pegaspargase	115
Priapism before and after hematopoietic stem cell therapy in individuals with sickle cell disease	113
Transfusion therapy for sickle cell disease: what’s new?	108
Best but not perfect: indirect measure of low iron stores	103
Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia	95
Kennedy VE, Wong C, Huang C-Y, et al. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv.	94
Campbell BA, Dobos G, Haider Z, et al. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood	93
Pirillo C, Birch F, Tissot FS, et al. Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Adv.	93
COVID-19 vaccination during therapy in relation to COVID-19 death in CLL	90
Steroid tapering after GVHD Rx: not too fast, not too slow	88
International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies	86
Stratifying survival: the role of social determinants of health on AML outcomes by ELN 2022 criteria	86
Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization	83
Matrix stiffness controls megakaryocyte adhesion, fibronectin fibrillogenesis, and proplatelet formation through Itgβ3	82
Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation	82
Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A	80
Real-world comparison of progression-free survival and time to next therapy in 761 patients with newly diagnosed multiple myeloma	79
Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction	77

Improvements in health-related quality of life in patients with transfusion-dependent β-thalassemia after exagamglogene autotemcel	76
Regional brain age is decreased in children with sickle cell anemia	74
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination	72
Complement C5 inhibition in early onset HELLP syndrome	71
Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019	70
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies	69
Persistence of PET scan positivity after chemoimmunotherapy for DLBCL	68
Converting IMPROVE bleeding and VTE risk assessment models into a fast-and-frugal decision tree for optimal hospital VTE prophylaxis	67
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis	67
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years	66
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi	65
Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network	65
HMA + venetoclax triplet regimens for the initial treatment of AML in adults- CONTRA	64
A mouse model for hemoglobin SC disease recapitulates characteristic human pathologies	62
ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV	62
Cystic fibrosis and sickle cell disease associated with nonadministration of VTE prophylaxis in hospitalized adults	62
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia	61
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial	61
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea	61
Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel	60
Myelodysplastic Syndromes in VEXAS	60
CD58 loss in tumor cells confers functional impairment of CAR T cells	59
LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signaling	59
Targeting bone marrow mesenchymal stromal cell–derived IL-6 to overcome acute myeloid leukemia chemoresistance	58
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model	58
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry	58
Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma	58
Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL	57
Longitudinal clinical data improve survival prediction after hematopoietic cell transplantation using machine learning	57
Complete absence of GLUT1 does not impair human terminal erythroid differentiation	57
Clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma	56
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML	56
Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease	55
Pediatric adapted risk index to predict 2-year transplant-related mortality post-HSCT in children	55
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma	54
Anti-CD19 CAR-T in transformed indolent lymphoma versus de novo large B-cell lymphoma: a meta-analysis of 5,006 patients	54
Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children	54
Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma	54
Gilteritinib and chemotherapy in children with relapsed/refractory FLT3 -ITD AML: results from the phase 1/2 SKIPPER trial	53
Selective modulation of activated protein C activities by a nonactive site–targeting nanobody library	53
A nested case-control study of monoclonal gammopathy of undetermined significance in the Multiethnic Cohort study	53
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia	53
Infections and parameters of humoral immunity with talquetamab in relapsed/refractory multiple myeloma in MonumenTAL-1	52
Reaching consensus in relapsed/refractory ALL in AYAs	52
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia	51
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool	50
Diagnostic criteria for NK cell large granular lymphocyte leukemia: validation through a multicentric international study	50
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes	50
Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation	50
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703	49

Structural analysis of platelet fragments and extracellular vesicles produced by apheresis platelets during storage	49
CAR T cells targeting CCR4 selectively deplete human Tregs ex vivo and in vivo	49
Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries	49
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel	49
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma	49
Predictors of post-transplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma	48
Long-term data needed for SCD gene therapy	48
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium	48
Applying CRISPR-Cas9 screens to dissect hematological malignancies	48
Transition from inpatient to outpatient step-up dosing of bispecific antibodies in multiple myeloma: real-world insights	48
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients	48
Genome-wide copy number profiling enhances risk stratification in multiple myeloma by shallow whole-genome sequencing	47
Platelet Rubicon drives thrombosis independent of autophagy	47
Guideline on the emergency management of critical bleeding in patients with immune thrombocytopenia	47
Evaluating complement dysregulation in livedoid vasculopathy using a functional assay	46
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study	46
Interpretation of response in BOS: the definitions remain key	46
D-dimer for patients on VKA vs DOAC: impact on the validity of D-dimer to make decision for extended anticoagulation	46
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial	46
Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?	46
Danazol treatment for telomere biology disorders: long-term results of a phase 1/2 study	46
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial	45
Neighborhood socioeconomic status and overall survival among children with acute lymphoblastic leukemia	45
FBXW7β isoform drives transcriptional activation of the proinflammatory TNF cluster in human pro-B cells	45
Tumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq	45
Cabozantinib and thromboembolism in patients with cancer: a systematic review, meta-analysis, and retrospective study	45
Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL	44
An αIIbβ3 ligand-mimetic murine monoclonal antibody that produces platelet activation by engaging the FcγIIa receptor	44
Distinguishing STAT3/STAT5B-mutated large granular lymphocyte leukemia from myeloid neoplasms by genetic profiling	44
Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study	44
Ibrutinib increases miR-181a/b in leukemic cells from patients with chronic lymphocytic leukemia	44
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes	43
Emerging from the shadows of congenital TTP	43
Return emergency department visits for recurrent pulmonary embolism symptoms in children and adolescents	43
Association between hemoglobin values and VWF assays: a multicenter investigation	42
Another step toward frontline BTK inhibitor therapy in MCL	42
Hasselbalch HC, Kristiansen MH, Kjær L, et al. CHIP- JAK2V617F , chronic inflammation, abnormal megakaryocyte morphology, organ failure, and multimorbidi	42
ASH's commitment to SCD: building on 10 years of progress	42
Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data. Blood Adv.	42
Severe parvovirus B19 infection in patients with sickle cell disease hospitalized in intensive care units	42
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease	42
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms	42
Anticoagulation, recurrent thrombosis, and major bleeding in antiphospholipid syndrome: UK multicenter observational study	42
Donor age contributes more to the rheological properties of stored red blood cells than donor sex and biological age distribution	41
Mitochondrial dsRNA from B-ALL cells stimulates mesenchymal stromal cells to become cancer-associated fibroblasts	41
Fanconi anemia neuroinflammatory syndrome: brain lesions and neurologic injury in Fanconi anemia	41
Graft-versus-host disease may cause pulmonary restriction, but not all restriction is graft-versus-host disease	41
Early steroid and anakinra use to manage axicabtagene ciloleucel toxicity reduces the total duration of CRS and ICANS	40
Adaptation of Serious Illness Care Program to be delivered via telehealth for older patients with hematologic malignancy	40
Spatial transcriptomics identifies a suppressive, T-cell excluded tumor microenvironment in extramedullary myeloma	40
Novel humanized loss-of-function NF1 mouse model of juvenile myelomonocytic leukemia	40
Uptake of long-chain fatty acids from the bone marrow suppresses CD8+ T-cell metabolism and function in multiple myeloma	40
POD24 is a novel determinant of prognosis in patients with Waldenström macroglobulinemia	40
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities	40
BCL2 overexpression in donor lymphocytes reduces the risk of graft-versus-host disease	40
Dasatinib-induced spleen contraction leads to transient lymphocytosis	40
AMPK drives both glycolytic and oxidative metabolism in murine and human T cells during graft-versus-host disease	39
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma	39
Are CHOP-plus really CHOP-minus propositions in the treatment of PTCL? A comprehensive assessment of the strategy	39
Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients	39
Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease	39
Mining single-cell transcriptomic data reveals distinct T-cell population in pediatric B-ALL and AML at diagnosis	39
High pulmonary hypertension risk by echocardiogram shortens survival in polycythemia vera	39
Implementation of hospital-based sickle cell newborn screening and follow-up programs in Haiti	39
U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes	39
Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma	39
Genetic and Laboratory Predictors of Bleeding Severity in FVII Deficiency: Insights from PRO-RBDD and EN-RBD Databases	39
Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy	38
Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities	38
Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma	38
Response to " Are statins interferons best friend? Mechanistic insights"	38
Growth and puberty in African children with sickle cell anemia treated with hydroxyurea	38
Efficacy of radiotherapy and role of adjunctive immunochemotherapy in POEMS syndrome with solitary plasmacytoma	38
Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML	38
A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease	37
Outcomes of radiation integrated with T-cell–engaging bispecific antibodies in relapsed/refractory multiple myeloma	37
Phase 1/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease	37
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis	37
PD-1 inhibition for relapse after allogeneic transplantation in acute myeloid leukemia and myelodysplastic syndrome	37
Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia	37

Recurrent VTE in patients with thrombophilia after stopping anticoagulation - A systematic review and meta-analysis	37
Polatuzumab vedotin–containing regimens as bridge to CART: analysis from the CART-SIE study	37
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma	37
Bridging two worlds: harmonizing pediatric and adult ALL	37
Seroprotection after Measles Vaccination in Children with Sickle Cell Anemia Receiving Hydroxyurea	37
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS	37
Long live the red blood cell: biotin tagging in SCD	36
Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy	36
Should we move to a genomic classification of neutrophilic myeloid neoplasms?	36
EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress	36
Bridging therapy before axi-cel for lymphoma	36
Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination	36
Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma	36
Commentary on the 2021 ASH Guidelines on use of anticoagulation in patients with COVID-19 being discharged from the hospital	36
IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence	36
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study	35
Interactions between integrin α9β1 and VCAM-1 promote neutrophil hyperactivation and mediate poststroke DVT	35
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma	35
Utilization patterns of hematology consultation in the intensive care unit: an 11-year single-center experience	35
AR expression in AML cells is same in female vs male patients	35
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia	35
Exploring the role of C1-inhibitor in thrombotic diseases	35
Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease	35
Age-associated hematopoietic variants in the rhesus macaque	34
Comments and concerns on the analysis of DAPS-ITP trial	34
Dual ASXL1 and CSF3R mutations drive myeloid-biased stem cell expansion and enhance neutrophil differentiation	34
Familial clusters and clinical features, complications, and outcomes in 1000 patients with Waldenström macroglobulinemia	34
Molecular profiling of primary renal diffuse large B-cell lymphoma unravels a proclivity for immune-privileged tropism	34
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group	34
Pregnancy after hematopoietic stem cell transplant: an international multicenter study	34
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates	34
Role of race and ethnicity in survival among children/young adults with relapsed ALL: a Children’s Oncology Group report	34
Thromboprophylaxis in hospitalized and nonhospitalized medical patients: what’s new?	34
Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?	34
RNA-regulatory exosome complex suppresses an apoptotic program to confer erythroid progenitor cell survival in vivo	34
Deciphering the regulatory landscape of murine splenic response to anemic stress at single-cell resolution	34
Cost-effectiveness of Voncento prophylaxis vs on-demand treatment in von Willebrand disease in the United Kingdom	34
Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia	34
Factor XI inhibitors: a new class of anticoagulants	34
Combinatorial targeting of epigenome-modifying enzymes with decitabine and RN-1 synergistically increases HbF	33
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial	33
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912	33
Population-scale analysis reveals inherited C1-inhibitor deficiency is a polyphenotypic thrombotic disorder	33
Gioacchino E, Koyunlar C, Zink J, et al. Essential role for Gata2 in modulating lineage output from hematopoietic stem cells in zebrafish. Blood Adv. 202	33
Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma	33
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse	33
Expanding donor options: haploidentical transplant recipients are also highly likely to have a 7/8-matched unrelated donor	33
Presentation of CXCL12γ by heparan sulfate proteoglycans activates CXCR4 without desensitization in normal and malignant B cells	33
Limitations of the epcoritamab vs odronextamab comparative analysis	33
The American Society of Hematology Health Equity Compendium: examining health equity across the Blood journals	33
Cutaneous dysbiosis characterizes the post–allogeneic hematopoietic stem cell transplantation period	33
Efficacy and safety of dapsone in adult primary immune thrombocytopenia	33
To pursue gene therapy or not? Is it feasible after graft failure in allogeneic hematopoietic cell transplant recipients	33
Effectiveness and safety of prophylactic anticoagulation among hospitalized patients with inflammatory bowel disease	33
Effect of rabbit ATG PK on outcomes after TCR-αβ/CD19–depleted pediatric haploidentical HCT for hematologic malignancy	32
Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs	32
Digital pathology in pediatric nodular lymphocyte-predominant Hodgkin lymphoma: correlation with treatment response	32
Cellular and biochemical heterogeneity contributes to the phenotypic diversity of transfusion-dependent β-thalassemia	32
Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms	32
Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study	32
HLA reduction of human T cells facilitates generation of immunologically multicompatible cellular products	32
A 69 long noncoding RNA signature predicts relapse and acts as independent prognostic factor in pediatric AML	32
Hydroxyurea pharmacokinetics, it is a small world after all	32
A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment	32
Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes	32
The use of FDA-approved medications for preventing vaso-occlusive events in sickle cell disease	32
Cytokine receptor IL27RA is an NF-κB–responsive gene involved in CD38 upregulation in multiple myeloma	32
Lineage switching of the cellular distribution of BRAF V600E in multisystem Langerhans cell histiocytosis	32
Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia	32
Long-term health outcomes in older recipients of blood or marrow transplantation: a report from the BMTSS	32
T-cell malignancies with anti-CD19 chimeric antigen receptor T-cell therapy	32
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD	32
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study	31
International consensus statement on the management of cardiovascular risk of Bruton’s tyrosine kinase inhibitors in CLL	31
Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study	31
Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis	31
Circulating S100A8/A9 drives faster platelet COX-1 recovery via MRP4, impairing the duration of aspirin response	31
KDIGO-defined kidney dysfunction predicts long-term outcomes in a multicenter cohort of adults with sickle cell disease	31
Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma	31
Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia	31
World Coalition on SCD launches, sparking global focus on SCD diagnosis and care	31
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma	31
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab	31
Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population	31
Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial	31
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma	30
Synthetic lethality of decitabine plus ATR inhibition for TP53 -mutated AML	30
Racial and socioeconomic status diversity and GVHD outcomes	30
Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH	30
Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation	30
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy	30
Do sophisticated models give the full picture of allogeneic hematopoietic stem cell transplantation effect?	30
Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignancies	30
Thyroid hormones contribute to JAK/STAT pathway abnormal activation, promoting T-cell lymphoma dissemination	30
Molecular profiling of primary renal marginal zone lymphoma reveals overlapping features with extranodal marginal zone lymphoma	30